These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12376955)

  • 1. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.
    Bovier PA; Bock J; Loutan L; Farinelli T; Glueck R; Herzog C
    J Med Virol; 2002 Dec; 68(4):489-93. PubMed ID: 12376955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.
    Bovier PA; Bock J; Ebengo TF; Frösner G; Glaus J; Herzog C; Loutan L
    J Med Virol; 2010 Oct; 82(10):1629-34. PubMed ID: 20827757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence.
    Van Herck K; Van Damme P
    J Med Virol; 2001 Jan; 63(1):1-7. PubMed ID: 11130881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G; Gizaris V; Papaevangelou G
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
    Schmidtke P; Habermehl P; Knuf M; Meyer CU; Sänger R; Zepp F
    Vaccine; 2005 Oct; 23(44):5127-32. PubMed ID: 16054733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an inactivated hepatitis A vaccine amongst Singaporeans.
    Guan R; Ng HS; Fock KM; Ho KY; Yap I; Kang JY; Chow WC; Chew CN; Ng C; Teo CJ
    Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):268-71. PubMed ID: 8629058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population.
    Rendi-Wagner P; Korinek M; Winkler B; Kundi M; Kollaritsch H; Wiedermann U
    Vaccine; 2007 Jan; 25(5):927-31. PubMed ID: 17005304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
    Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H
    Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial.
    Jiang WP; Chen JT; Wang X; Wang YL; Liu Y; Chen WY; Xu WG; Qiu YZ; Yin WD
    Vaccine; 2008 Apr; 26(18):2297-301. PubMed ID: 18395305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenicity and long-term persistence of anti-HAV in groups with different attenuated and inactived hepatitis A vaccine dosage].
    Wang X; Ma J; Zhang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Apr; 22(2):111-3. PubMed ID: 11860857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children].
    Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of immunology effects between live attenuated hepatitis A vaccine and inactivated hepatitis A vaccine].
    Wang X; Meng Z; Li R
    Zhonghua Yi Xue Za Zhi; 2000 Jun; 80(6):422-4. PubMed ID: 11798797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune response to a single dose of a novel kind of hepatitis A vaccine following splenectomy].
    Simmen HP; Robustelli L; Althaus B; Glück R; Trentz O; Vogt M
    Dtsch Med Wochenschr; 1996 Mar; 121(10):295-8. PubMed ID: 8681712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
    Maiwald H; Jilg W; Bock HL; Löscher T; Sonnenburg F
    Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.